A Phase 1/2, Open-Label, Dose Escalation, Safety and Tolerability Study of INCB050465 and Itacitinib in Subjects With Previously Treated B-Cell Malignancies (CITADEL-101)

Nyu Langone Laura and Isaac Perlmutter Cancer Center, New York

Greenville Health System Cancer Institute, Greenville

University of Alabama At Birmingham Comprehensive Cancer Center, Birmingham

University Hospitals Case Medical Center, Cleveland

University of Michigan Cancer Center, Ann Arbor

Karmanos Cancer Institute, Detroit

Baylor Charles A. Sammons Cancer Center, Dallas